CEO, Summit Orthopedics
As Chief Executive Officer, Adam is leading strategic, financial and operational planning and implementation for the organization with over 60 physicians, 800+ employees and 35+ clinical sites of service. Influence and report to an 8 shareholder member Board of Directors. Doubled the revenues in six years through organic growth, new service offerings, and strategic acquisitions.
Vice President of Corporate Development, Medtronic
Chris Cleary has been Vice President of Corporate Development for Medtronic since 2014. During this period, he has led more than 40 acquisitions with consideration of $56 billion, including notable deals like Covidien, NGC, Twelve, Smith & Nephew TruClear, HeartWare, Mazor Robotics and Epix. Chris also led the sale of portions of Medtronic’s non-strategic medical supplies business to Cardinal for $6 billion.
Co-Editor-in-Chief, MedTech Strategist
David Cassak has more than 30 years of experience in the healthcare industry. Cassak co-founded Windhover Information Inc., and also served as Vice President, Content, and Managing Director, Medical Devices for Elsevier Business Intelligence, a Reed Elsevier Company which included the publications In Vivo, Startup, RPM Report, Medtech Insight, The Gray Sheet and The Pink Sheet.
Dianna El Hioum
Partner, Fox Rothschild LLP
Dianna centers her practice on global patent prosecution, licensing and opinion work. With a background in biotechnology, chemistry and large-scale drug manufacturing, she understands the development of drugs and medical devices, from early stage research and patenting to FDA-approval, production and marketing. In addition to her experience in the chemical and pharmaceutical industries, Dianna handles intellectual property issues in the area of shooting sports.
Stacy Enxing Seng
Venture Partner, Lightstone Ventures
Stacy is a Venture Partner of LSV and assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. Stacy currently serves as an Independent Director for both public and venture-backed private companies in director and committee member roles. An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and world-class company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture. Prior to Independent Director work, Stacy spent the last 25 years in medtech, most recently serving as the President of Covidien’s $1.7B Vascular Therapies business. Stacy joined Covidien following its $2.6B acquisition of ev3 Inc., a medical technology start-up success that Stacy co-created in 2000 with ev3’s founding team. Over the course of her career Stacy has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions, and under her operating leadership, a reputation of achieving world class customer and employee engagement.
President & CEO, Cardionomic
Steve Goedeke’s extensive experience spans implantable defibrillators, pacemakers, therapies for heart failure, device design, and wireless communications. Before joining Cardionomic as President and CEO, Goedeke was President and CEO at Denali Medical II and previously served as a Senior Director within Medtronic’s Cardiac Rhythm Disease Management division. He is a Bakken Fellow and was largely responsible for the creation of the MICS wireless system. He is also a two-time recipient of Medtronic’s Star of Excellence and was granted The Chairman’s Award for Outstanding Initiative. Before his 17 years at Medtronic, Goedeke held various technical and business development roles at Hewlett-Packard. Goedeke is a named inventor on 25 patents and holds a B.S in electrical engineering from Washington University in St. Louis and a M.S. in electrical engineering from the University of Illinois at Urbana-Champaign.
Managing Director, Global Head of Medtech, Locust Walk
Hunt Henrie joined Locust Walk as a Managing Director in 2017, and has spent the last 15 years at Ferghana Partners where he started and led the Medical Technology and Financing activities. At Locust Walk Hunt is responsible for the firm’s Medical Technology practice. Hunt brings to Locust Walk over 30 years of broad-based global financial, investment banking, private equity and corporate operating experience, of which the last 26 have been in healthcare. He has lived and worked overseas for 15 years including over six years in Paris and London. Hunt began his career with Chase Manhattan/JP Morgan and was a founding member of Chase’s European Mezzanine Capital Group which later became Chase/JP Morgan Partners Europe. Hunt spent six years operating in the biomedical industry with Instrumentation Laboratory where he was Managing Director for Worldwide Corporate Finance and CFO of IL’s US subsidiary.
President & CEO, Relievant MedSystems
Kevin Hykes is the CEO and President of Relievant Medsystems, a privately held medical device company that has developed the Intracept® procedure, a breakthrough treatment for chronic lower back pain. Prior to Relievant Kevin was an Operating Partner at Versant Ventures and Chairman and CEO of Metavention, Inc., CEO of Cameron Health, Chief Commercial Officer of Visiogen, Inc. and spent sixteen years at Medtronic in the CRM, Neurostimulation, and Cardiac Surgery businesses. Kevin received his MBA from Northwestern University and a BBA from the University of Wisconsin. Kevin is an independent director at Metavention and Veran Medical Technologies.
Principal, Arboretum Ventures
In his current role as Principal, Dan focuses on supporting Arboretum's portfolio companies and leading new investments across the firm’s sectors of interest, with particular emphasis on life science tools. Since joining Arboretum, Dan has undertaken significant due diligence responsibilities to support more than a dozen of Arboretum’s new and follow-on investments, including Ebb Therapeutics, NeuMoDx, IntelliCyt, Rethink, Cardiac Dimensions, Strata Oncology, SI-BONE, Swift Biosciences and Dropworks. Dan’s portfolio company involvement has included serving on the board of directors for life science tools company IntelliCyt. Dan currently serves on the Board of Directors for Swift Biosciences, Dropworks and as a board observer for NeuMoDx and Strata Oncology. Prior to joining Arboretum, Dan was a Financial Analyst at Eli Lilly & Company, supporting the company’s U.S. sales and marketing operations.
Laura G. King
Founder & CEO, Elucent Medical, Inc.
Ms. King is Founder and CEO of Elucent Medial, an Eden Prairie, MN based medical device company that has developed the EnVisioTM wireless surgical navigation platform with a first clinical indication in breast surgery. Prior to Elucent, Ms. King led NeuWave Medical, a Madison, WI based start-up that developed and commercialized a device to ablate cancer tumors in liver, kidney, lung and bone. Ms. King led NeuWave Medical for seven years, successfully raising $33 M in venture capital and doubling revenue each year. NeuWave had a very successful exit, selling to JnJ Ethicon for $300M in 2016. Prior to joining the start-up world, Ms. King was a GE company officer leading the $1.2 B Global Interventional Cardiology and Surgery business. Ms. King is also co-owner of Vino Veritas, a WI wine distribution company. Raised in San Francisco, CA, she is a graduate of UC Davis in Economics.
Partner, Fox Rothschild
Patrice advises medical technology companies, digital health care companies, other emerging businesses and venture capital investors in a broad range of business and commercial matters, including venture capital financings, private placements, venture debt and credit facilities, mergers and acquisitions and securities compliance. She also delivers sound legal counsel to lenders in commercial loan transactions, including $100 million+ loan facilities, and advises clients on equity financing structures and clinical trial agreements. In addition, she routinely provides guidance to boards of directors on fiduciary duties and corporate governance obligations. Prior to joining Fox Rothschild, Patrice was a partner at Oppenheimer Wolff & Donnelly LLP, where she served as co-chair of the firm’s MedTech Practice Group and a member of the firm’s Policy Committee.
Co-Editor-in-Chief and Managing Partner
Stephen served as Executive Editor & General Counsel at Windhover Information followed by Editor-in-Chief of Medical Devices for Elsevier Business Intelligence, where he directed the company’s editorial coverage of the medical device industry. Before that, Stephen was Senior Counsel to the US Senate Permanent Subcommittee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations including the Whitewater inquiry. Before joining the Subcommittee, he was with the Federal Election Commission and the Department of Justice.
President & CEO, The Medical Alley Association
Shaye has served as President & CEO of The Medical Alley Association since May, 2014. During this tenure, the association has undertaken significant transformation to focus on championing and facilitating an environment that enables health technology and care organizations to innovate, succeed, and influence the evolution of healthcare. Under Mr. Mandle’s leadership, the association’s vision is to elevate Minnesota’s Medical Alley as the global epicenter of health innovation and care. Mr. Mandle has more than 20 years of experience in government, the private sector and academia, leading organizations, public affairs and political activities. From 2011-2014, Mr. Mandle served as the association’s EVP & COO and its VP of Government & Affiliate Relations. Prior to joining The Medical Alley Association, Mr. Mandle served as the ED of the FedEx Institute of Technology at the University of Memphis, where he launched and oversaw the University Office of Technology Transfer and led the University’s corporate partnership, entrepreneurship and economic development programming.
VP Strategy & Business Development, Health Care Business Group, 3M
Aaron leads strategy and business development for 3M's Health Care Business Group, a $6B global leader in medical and oral care products, drug delivery systems, health information systems, and food safety systems -- supplying advanced technology that helps medical professionals to improve the quality of care for millions of people while managing overall costs. Before joining 3M, Aaron held executive leadership roles across operations, corporate development and strategy at Phillips-Medisize and Remedi SeniorCare, both private equity backed healthcare businesses. He started his career as a consultant with Bain & Company, spending significant time in med-tech and on international assignments.
Vice President of New Business Development, Johnson & Johnson
As Vice President of Business Development and a member of the Medical Devices Group Operating Committee, Susan has responsibility for licensing, acquisitions and divestitures for the Medical Devices Group. Susan joined J&J as a college recruit in the Finance organization. During her tenure in the Corporation, she transitioned through a number of positions with increasing responsibility through six operating companies, primarily within Finance and Business Development. Susan has been involved in a number of significant transactions within Medical Devices.
Managing Director, Versant Ventures
Kirk Nielsen is a Managing Director at Versant Ventures, where he leads the firm's med tech practice. Before joining Versant in 2006, Kirk worked at Medtronic, Fluidigm, and Bain & Company. Prior to his business career, Kirk was a professional hockey player. Kirk graduated with a BA in Biology from Harvard College, where he won the John P. Reardon award as the school's top scholar-athlete, and he earned an MBA from Harvard Business School, where he was a Baker Scholar.
President and CEO, 4C Medical Technologies, Inc.
Mr. Thatcher has over 35 years of executive and c-level experience in the medical device industry, varying from growing pre-clinical private companies to growing public companies with a market cap of over $1 billion. Prior to 4C Medical, Mr. Thatcher led functional teams in Sales & Marketing, Manufacturing, R&D, Quality, Regulatory, Clinical and Healthcare Policy at Cardiovascular Systems, Inc. Earlier in his career, Mr. Thatcher held positions in commercial management, general management and executive management at Boston Scientific, Schneider and Medtronic where he managed teams throughout the business including Sales, Marketing, Regulatory, Clinical and Reimbursement. He primarily focused on building high performance teams capable of reducing costs and compressing timelines while improving quality and achieving business goals.
Executive Vice President and President of Diversified Business, Blue Cross and Blue Shield of Minnesota
Tom Vanderheyden oversees all strategies for expanding diversified business investments, bringing new health care products and solutions to market, and commercializing existing products and services. Additionally, he has responsibility for all aspects of internal and external communications; the Blue Cross and Blue Shield of Minnesota Foundation; community health and health equity work, corporate social responsibility strategies and community relations initiatives.
Prior, Vanderheyden held multiple leadership roles over the course of 13 years at UnitedHealth Group (UHG). In 2015, he co-founded and served as CEO at Harken Health Insurance Company, an independently operated affiliate of UHG. His tenure at UHG also included leadership positions in business development and innovation; UnitedHealth International; global operations; strategic sourcing; and mergers and acquisitions.
Vice President, Strategic Market Partnerships, UnitedHealthcare Technology
Meyrick Vaz leads strategic market partnerships within the UnitedHealthcare Office of the CIO. In this role, he closely tracks emerging trends and developments in healthcare, while scouting for innovation that aligns with UnitedHealthcare's business agenda. He is responsible for identifying, evaluating, piloting, scaling up and rolling out new, untested ideas and approaches that could improve patient experience and increase provider satisfaction. Meyrick has more than 25 years of business technology leadership experience in industries like healthcare, financial services, retail, information services and consulting.
Founder, St. Jude Medical
Manny Villafaña, a nationally recognized entrepreneur and medical device developer. In 1972, he founded CPI/Guidant and developed the first lithium powered pacemakers and defibrillators. This technology is incorporated in virtually every defibrillator and pacemaker in the world. This is the most commonly use prosthesis in the world. The company was purchased by Boston Scientific for $27 billion. In 1976, he became the co-developer of the St. Jude heart valve and founder of St. Jude Medical Inc. Abbott Medical of Chicago recently paid $30 billion for St. Jude Medical.
Partner, Baird Capital
Nicole Walker joined Baird Capital's Venture Capital team in 2013 and focuses on early-to-growth stage healthcare investments. Nicole is a current member of the board of directors at Amphora Medical, Elucent Medical, MI Bioresearch, NeoChord, Inc, NeuMoDx Molecular, and Strata Oncology. She is also a Life Science Council member for Springboard Enterprises, an accelerator program dedicated to building high-growth technology-oriented companies led by women. Prior to joining Baird Capital, Nicole was a venture investor with Abbott focusing on early stage biotech, device, and diagnostic opportunities; and prior to that with Onset Ventures, a Menlo Park, CA firm that specializes in seed & early staged healthcare and tech service investments.